Journal Mobile Options
Table of Contents
Vol. 70, No. 4, 2001
Issue release date: July–August 2001
Psychother Psychosom 2001;70:221–225
(DOI:10.1159/000056257)

Sexual Dysfunction in Male Psychiatric Outpatients: Validity of the Massachusetts General Hospital Sexual Functioning Questionnaire

Labbate L.A. · Lare S.B.
Department of Psychiatry and Behavioral Science, Medical University of South Carolina, and VA Medical Center, Charleston, S.C., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The purpose of this study was to determine the frequency of sexual dysfunction in male outpatients with concomitant psychiatric and medical conditions and to establish the validity of the Massachusetts General Hospital Sexual Function Questionnaire (MGH). Methods: Male VA outpatients were given two sexual function questionnaires, a 36-item Changes in Sexual Functioning Questionnaire (CSFQ) and the 5-item MGH. Medical records were evaluated for diagnosis, medications and illnesses that might affect sexual functioning. Results: Among 100 outpatient respondents, the CSFQ showed that 90% and the MGH showed that 77% experienced sexual dysfunction. Forty percent of patients reported total absence of sexual function. Good concurrent validity was established between the MGH and CSFQ. Conclusions: Sexual dysfunction is highly prevalent in psychiatric outpatients. The MGH is a valid clinical measure to determine sexual dysfunction.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537–544.
  2. Seidman SN, Rieder RO: A review of sexual behavior in the United States. Am J Psychiatry 1994;151:330–341.
  3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB: Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61.
  4. Spector IP, Carey MP: Incidence and prevalence of the sexual dysfunctions: A critical review of the empirical literature. Arch Sex Behav 1990;19:389–408.
  5. Segraves RT: Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989;46:275–284.

    External Resources

  6. Balon R, Yeragani VK, Pohl R, Ramesh C: Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 1993;54:209–212.
  7. Labbate LA, Grimes JB, Arana GW: Serotonin reuptake antidepressant effects on sexual function in patients with anxiety disorders. Biol Psychiatry 1998;43:904–907.

    External Resources

  8. Jefferson JW: Psychotropic medications and their effects on sexual function. J Clin Psychiatry 1995;56:536–537.

    External Resources

  9. Margolese HC, Assalian P: Sexual side effects of antidepressants: A review. J Sex Marital Ther 1996;22:209–217.
  10. Barksdale JD, Gardner SF: The impact of first-line antihypertensive drugs on erectile dysfunction. Pharmacotherapy 1999;19:573–581.

    External Resources

  11. Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB: The relationship between depressive symptoms and male erectile dysfunction: Cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998;60:458–465.
  12. Clayton AH, McGarvey EL, Clavet GJ: The Changes in Sexual Functioning Questionnaire (CSFQ): Development, reliability, and validity. Psychopharmacol Bull 1997;33:731–745.
  13. Derogatis LR, Melisaratos N: The DSFI: A multidimensional measure of sexual functioning. J Sex Marital Ther 1979;5:244–281.
  14. Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ: An open trial of oral sildenafilin antidepressant-induced sexual dysfunction. Psychother Psychosom 1998;67:328–331.
  15. McGahuey C, Gelenberg AJ, Laukes CA, Manber R, McKnight K, Delgado PL: The Arizona Sexual Experience Scale: Validity and reliability. New Research 184 American Psychiatric Association Annual Meeting, May 17–22 1997, pp 116–117.
  16. Derogatis LR: The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): An introductory report. J Sex Marital Ther 1997;23:291–304.
  17. Conte HR: Development and use of self-report techniques for assessing sexual functioning: A review and critique. Arch Sex Behav 1983;12:555–576.

    External Resources

  18. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De la Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin T, Perez V, Sanchez JM, Sanchez S, Vicens E: SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176–194.
  19. Lewis CE: Sexual practices: Are physicians addressing the issues? J Gen Intern Med 1990;5:S78–S81.

    External Resources

  20. Schneider G, Kruse A, Nehen HG, Senf W, Heuft G: The prevalence and differential diagnosis of subclinical depressive syndromes in inpatients 60 years and older. Psychother Psychosom 2000;69:251–260.
  21. Condra M, Morales A, Owen JA, Surridge DH, Fenemore J: Prevalence and significance of tobacco smoking in impotence. Urology 1986;27:495–498.

    External Resources

  22. Forsberg L, Gustavii B, Hojerback T, Olsson AM: Impotence, smoking, and beta-blocking drugs. Fertil Steril 1979;31:589–591.

    External Resources

  23. Antonuccio DO, Danton WG, De Nelsky GY, Greenberg RP, Gordon JS: Raising questions about antidepressants. Psychother Psychosom 1999;68:3–14.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50